Filing Analysis
Anebulo Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the quarter ended December 31, 2025, and provided a general business update.
🚩 Red Flags
- Interim CFO role suggests potential recent turnover in financial leadership, though no specific departure was detailed in this text.
📋 Key Facts
- Report date: February 12, 2026
- Reporting period: Quarter ended December 31, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Richard Anthony Cunningham is serving as both CEO and Interim CFO.
Anebulo Pharmaceuticals, Inc. has announced the voluntary delisting of its common stock from the Nasdaq Capital Market and the subsequent deregistration of its securities with the SEC. This move is intended to terminate all periodic reporting obligations under the Securities Exchange Act of 1934.
🚩 Red Flags
- Voluntary delisting and deregistration typically indicates a move toward becoming a private company or a significant reduction in liquidity/transparency.
- Termination of reporting obligations (Form 15) removes public access to financial data, making it difficult for investors to track performance.
- The transition from a Nasdaq-listed entity to a non-reporting entity is often a precursor to insolvency or a complete shift in corporate structure.
📋 Key Facts
- Board approved voluntary delisting from Nasdaq on February 5, 2026.
- Company intends to file Form 25 (Notification of Removal from Listing) on or about February 17, 2026.
- Delisting is expected to become effective on February 27, 2026.
- Company intends to file Form 15 on or about February 27, 2026, citing fewer than 300 shareholders of record.
- Upon filing Form 15, the company's obligation to file periodic reports with the SEC will be suspended.
Anebulo Pharmaceuticals announced the final results of its tender offer to repurchase up to 300,000 shares of common stock at $3.50 per share. The offer was significantly oversubscribed, with 4,907,881 shares tendered, resulting in a proration factor of approximately 3.47%.
🚩 Red Flags
- Significant oversubscription suggests high demand for liquidity or a perceived price discrepancy between market and tender offer.
📋 Key Facts
- Tender offer price: $3.50 per share in cash.
- Total shares offered for purchase: 300,000 shares.
- Total shares tendered: 4,907,881 shares (oversubscribed).
- Aggregate cost of accepted shares: approximately $1.05 million.
- Proration factor: 3.47392% (except for odd lots which were accepted in full).
- Shares accepted represent ~0.73% of outstanding shares as of Jan 26, 2026.
Anebulo Pharmaceuticals announced the preliminary results of a tender offer to repurchase up to 300,000 shares at $3.50 per share. The offer was significantly oversubscribed, with approximately 4.89 million shares tendered.
🚩 Red Flags
- Significant oversubscription suggests a large portion of shareholders may be looking to exit their positions at the current price level.
📋 Key Facts
- Tender offer price: $3.50 per share in cash.
- Total shares offered for purchase: 300,000 shares.
- Total shares tendered: 4,897,188 shares (excluding guaranteed delivery).
- The offer was oversubscribed with a preliminary proration factor of approximately 3.51542%.
- Aggregate cost for the company is approximately $1.05 million.
- Tender offer expired on January 26, 2026.
Anebulo Pharmaceuticals is abandoning its planned massive reverse stock split (up to 1-for-7,500) in favor of a cash tender offer to buy back up to 300,000 shares at $3.50 per share. This pivot is intended to facilitate a 'go private' transaction by reducing the total number of stockholders below the 300-share threshold.
🚩 Red Flags
- Abandonment of a massive reverse stock split (up to 1-for-7,500) suggests extreme downward pressure on share price or delisting risk.
- Shareholder behavior: Investors are actively splitting holdings into sub-2,500 share accounts to capture fractional payments, indicating high volatility/distress.
- The company is attempting to 'go private' likely due to the inability to maintain Nasdaq listing requirements (minimum stockholders/share price).
📋 Key Facts
- Company intends to commence a cash tender offer for up to 300,000 shares of common stock at $3.50 per share.
- Aggregate purchase price of the tender offer is up to $1,050,000.
- The company is abandoning a previously announced reverse stock split (ratio between 1-for-2,500 and 1-for-7,500).
- Reason for abandonment: High costs associated with fractional share payments caused by shareholders splitting holdings into multiple accounts to exploit the split.
- The tender offer is designed to help the company maintain fewer than 300 stockholders to facilitate a 'go private' transaction.
Anebulo Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025, and provided a general business update via press release.
🚩 Red Flags
- Interim CFO role suggests potential recent turnover or instability in the finance department, though common in micro-caps.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
- Richard Anthony Cunningham is serving as both CEO and Interim CFO.
Anebulo Pharmaceuticals, Inc. issued an 8-K to furnish its quarterly and fiscal year financial results for the period ended June 30, 2025, along with a general business update.
📋 Key Facts
- Report date: September 29, 2025
- Financial results released for the quarter and fiscal year ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) providing a business update
- Company is an emerging growth company
Anebulo Pharmaceuticals, Inc. issued a press release regarding an update on a proposed 'going private' transaction and the evaluation of strategic alternatives.
🚩 Red Flags
- Discussion of 'strategic alternatives' often signals liquidity issues or the need for a major structural change to avoid insolvency.
- A 'going private' transaction can be used to delist from public exchanges, potentially reducing liquidity for minority shareholders.
📋 Key Facts
- The company is considering a potential going-private transaction.
- The company is evaluating various strategic alternatives as of September 12, 2025.
- The announcement was made via a press release filed as Exhibit 99.1.
Anebulo Pharmaceuticals has approved a massive reverse stock split (1-for-2,500 to 1-for-7,500) as part of a plan to go private and delist from Nasdaq. The transaction aims to reduce the number of record holders below 300 to terminate SEC reporting obligations.
🚩 Red Flags
- Extreme reverse stock split ratio (up to 1-for-7,500) typically indicates severe capital structure distress or an attempt to clear out small shareholders.
- Forced cash-out mechanism for minority shareholders owning below a specific threshold.
- Intent to terminate SEC reporting and delist from Nasdaq (going private via reduction of record holders).
- Significant dilution/liquidation risk for retail investors holding small positions.
📋 Key Facts
- Reverse stock split ratio: between 1-for-2,500 and 1-for-7,500.
- The split is part of a 'going private' transaction intended to delist from Nasdaq and terminate SEC reporting obligations.
- Stockholders owning fewer than the 'Minimum Number' (2,500 to 7,500 shares) will receive a cash payment of $3.50 per share instead of stock.
- A Special Meeting of Stockholders is expected on August 22, 2025, to vote on the proposal.
- The company filed a preliminary proxy statement and Schedule 13E-3 on July 23, 2025.
Anebulo Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly financial results and a business update for the period ended March 31, 2025.
📋 Key Facts
- The filing is related to Item 2.02 (Results of Operations and Financial Condition).
- Financial results were announced on May 13, 2025.
- The reporting period covers the quarter ended March 31, 2025.
- A press release containing the business update is attached as Exhibit 99.1.
Anebulo Pharmaceuticals announced that Nasdaq has closed its compliance matter regarding Listing Rule 5635(b). The company successfully regained compliance following the removal of certain voting and transfer restrictions on shares from a December 2024 private placement.
🚩 Red Flags
- Previous non-compliance with Nasdaq Listing Rule 5635(b) regarding share restrictions (now resolved).
📋 Key Facts
- Nasdaq notified the Company on April 11, 2025, that it has closed the matter regarding potential non-compliance with Listing Rule 5635(b).
- Compliance was achieved following stockholder approval to remove voting and transfer restrictions on common stock issued in a December 2024 private placement.
- The company is currently an 'Emerging Growth Company'.
- The matter was previously disclosed via an 8-K filed on April 7, 2025.
Anebulo Pharmaceuticals announced that stockholders approved several corporate governance and structural changes during the 2025 Annual Meeting. These include increasing authorized share count, declassifying the Board of Directors, and updating company bylaws.
🚩 Red Flags
- Increase in authorized share count (from 50M to 75M) can lead to future equity dilution if used for capital raises.
📋 Key Facts
- Stockholders approved an amendment to increase authorized common stock from 50,000,000 to 75,000,000 shares on April 4, 2025.
- The 'Declassification Charter Amendment' was approved to transition the Board of Directors to annual elections (one-year terms) starting at the next annual meeting.
- The Company filed the Share Increase and Declassification amendments with the Secretary of State of Delaware on April 11, 2025.
- Bylaws were amended to include conforming language regarding board declassification.
Anebulo Pharmaceuticals, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on April 4, 2025. Shareholders approved several key structural changes, including board declassification and a significant increase in authorized share count.
🚩 Red Flags
- Significant increase in authorized share count (from 50M to 75M) and incentive plan pool suggests potential future dilution for existing shareholders.
📋 Key Facts
- Stockholders approved an amendment to the 2020 Incentive Plan, increasing available shares from 3,650,000 to 6,150,000.
- The Board of Directors was declassified via a charter amendment.
- Authorized common stock was increased from 50,000,000 to 75,000,000 shares.
- Three directors (Joseph F. Lawler, Richard Anthony Cunningham, and Aron R. English) were elected to one-year terms.
- EisnerAmper LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- Voting restrictions on 10,101,010 shares held by 22NW Fund, LP were removed.
Anebulo Pharmaceuticals received a notice from Nasdaq regarding non-compliance with Rule 5635(b) following a change of control triggered by a private placement. The company has entered into a lock-up agreement with the new controlling shareholder to regain compliance and must obtain stockholder approval by April 10, 2025, to avoid delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq Rule 5635(b)
- Change of control resulting from private placement without prior shareholder approval
- Significant concentration of voting power (Aron English controls >51% subject to lock-up)
- Risk of delisting if stockholder approval is not obtained by April 10, 2025
📋 Key Facts
- Nasdaq notified the company on February 20, 2025, of failure to comply with Rule 5635(b) regarding change of control without stockholder approval.
- Aron English (via 22NW Fund, LP) became the largest stockholder, owning >50% of voting power following a Dec 2024 private placement.
- The company entered into a Lock-Up Agreement with 22NW on February 24, 2025, restricting the sale and voting of 10,101,010 shares.
- Nasdaq granted an extension until April 10, 2025, to obtain stockholder approval for the removal of these restrictions.
- A shareholder meeting is scheduled for April 4, 2025, to vote on removing the lock-up restrictions.
- Joseph Lawler and related entities have entered into a Support Agreement with 22NW to vote in favor of the proposal.
Anebulo Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly financial results for the period ended December 31, 2024, and a general business update via press release.
📋 Key Facts
- Report date: February 14, 2025
- Reporting period: Quarter ended December 31, 2024
- The filing includes Exhibit 99.1 containing the financial results and business update.
Anebulo Pharmaceuticals announced the scheduling of its 2025 Annual Meeting of Stockholders for April 4, 2025. The filing provides revised deadlines for stockholder proposals and director nominations to comply with SEC rules.
📋 Key Facts
- Annual Meeting of Stockholders scheduled for April 4, 2025.
- Deadline for Rule 14a-8 stockholder proposals: February 22, 2025.
- Deadline for director nominations or other non-Rule 14a-8 proposals: February 22, 2025.
- Deadline for stockholders intending to solicit proxies under Rule 14a-19: February 22, 2025.
Anebulo Pharmaceuticals entered into a $15 million private placement with 22NW Fund, LP, an entity controlled by Director Aron English. This transaction results in Mr. English gaining voting power over more than 50% of the company's common stock, triggering a change in control.
🚩 Red Flags
- Related-party transaction: The primary investor is controlled by a sitting Director.
- Change in control: A director now holds majority voting power (>50%).
- Potential dilution: Issuance of over 15 million shares at the Nasdaq minimum price.
- Registration requirement: Company must register these shares for resale, creating potential future selling pressure.
📋 Key Facts
- Private placement of 15,151,514 shares at $0.99 per share (Nasdaq Minimum Price).
- Aggregate gross proceeds of approximately $15 million.
- 22NW Fund, LP is a greater than 5% stockholder controlled by Director Aron English.
- Transaction results in Mr. English holding >50% of all issued and outstanding shares.
- Company will file a registration statement for the resale of these shares within 60 days.
- The company is modifying its Loan and Security Agreement (LSA) with 22NW to reduce maximum loan size to ~$3 million.
Anebulo Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly earnings press release and business update for the period ended September 30, 2024.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and a business update.
- Company is an emerging growth company.
Anebulo Pharmaceuticals, Inc. has updated its Corporate Presentation to provide investors with current information regarding the company's operations and outlook.
📋 Key Facts
- The filing is an update to the Company's Corporate Presentation dated October 17, 2024.
- The presentation is furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure).
- The information provided in the presentation is not considered 'filed' for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.
Anebulo Pharmaceuticals, Inc. issued an 8-K to furnish its quarterly and fiscal year financial results for the period ended June 30, 2024, alongside a general business update.
📋 Key Facts
- Report date: September 25, 2024
- Reporting period covered: Quarter and Fiscal Year ended June 30, 2024
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an 'Emerging Growth Company'
Anebulo Pharmaceuticals announced the receipt of the first tranche of a two-year cooperative grant from the National Institute on Drug Abuse (NIH). The total potential funding is approximately $1.9 million to support the development of intravenous selonabant for treating acute cannabis-induced toxicities.
📋 Key Facts
- Awarded a two-year cooperative grant by the National Institute on Drug Abuse (part of NIH) under award number 1U01DA059995-01.
- Total potential funding is approximately $1.9 million.
- Funding is structured in two tranches: an initial $0.9 million and a subsequent ~$1 million subject to milestones.
- The grant supports the development of intravenous selonabant for emergency treatment of acute cannabis-induced toxicities (including CNS depression in children).
Anebulo Pharmaceuticals, Inc. announced the Board's approval of a new non-employee director equity compensation policy. The policy establishes both initial and annual stock option grants for non-employee directors to align their interests with shareholders.
📋 Key Facts
- Board approved a new 'Director Equity Compensation Policy' on June 13, 2024.
- Initial award: Option to purchase 50,000 shares of common stock per director, vesting pro rata monthly over three years.
- Annual award: Option to purchase 25,000 shares of common stock per director, vesting on the one-year anniversary or at the next annual meeting.
Anebulo Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended March 31, 2024 and provide a general business update.
📋 Key Facts
- The filing pertains to financial results for the quarter ended March 31, 2024.
- The company issued a press release (Exhibit 99.1) containing its quarterly earnings and business update.
- The report was filed on May 15, 2024.
Anebulo Pharmaceuticals, Inc. issued an 8-K to announce its financial results for the quarter ended December 31, 2023, and provided a general business update.
📋 Key Facts
- Report date: February 13, 2024
- Reporting period: Quarter ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
- Company is an emerging growth company.